Open-label Extension Study to Evaluate the Safety of USL255 in Patients With Refractory Partial-onset Seizures

Phase 3CompletedNCT01191086

Upsher-Smith Laboratories210 enrolled

Overview

The purpose of this study is to examine the safety of USL255 as adjunctive therapy in patients with refractory partial onset-seizures.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

210

Conditions

Epilepsy

Interventions

USL255DRUG

Eligibility

Sex: ALLMin age: 18 YearsMax age: 75 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Have completed the maintenance period of the P09-004 study. * Continue to be treated with a stable dose of 1 to a maximum of 3 approved concomitant AEDs.

Locations (68)

Outcomes

Primary Outcomes

Evaluate the Safety of USL255 Through the Collection of Adverse Events and Clinical Laboratory Evaluations

Time frame: Open label treatment of up to 62 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Unnamed facility

Phoenix, Arizona, United States

Unnamed facility

Ventura, California, United States

Unnamed facility

Gainsville, Florida, United States

Unnamed facility

Gulf Breeze, Florida, United States

Unnamed facility

Jacksonville, Florida, United States

Unnamed facility

Port Charlotte, Florida, United States

Unnamed facility

Lexington, Kentucky, United States

Unnamed facility

Waldorf, Maryland, United States

Unnamed facility

Chesterfield, Missouri, United States

Unnamed facility

St Louis, Missouri, United States

...and 58 more locations